"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022 12; 28(15 Suppl):S297-S306.
-
Amaro A, Skolnik NS, Sugimoto D. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022 Jan; 134(sup1):18-27.
-
Kyrillos JV, Skolnik NS, Mukhopadhyay B, Pennings N. Integrating semaglutide into obesity management - a primary care perspective. Postgrad Med. 2022 Jan; 134(sup1):37-49.
-
Kyrillos JV, O'Neil PM, Wharton S. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgrad Med. 2022 Jan; 134(sup1):1-4.
-
Zupa MF, Codario RA, Smith KJ. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. J Comp Eff Res. 2021 10; 10(15):1133-1141.
-
Morales J, Shubrook JH, Skolnik N. Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgrad Med. 2020 Nov; 132(8):687-696.
-
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 10 17; 318(15):1460-1470.
-
Ozudogru SN, Lippa CF. Disease modifying drugs targeting ?-amyloid. Am J Alzheimers Dis Other Demen. 2012 Aug; 27(5):296-300.
-
Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006 Jun; 317(3):1106-13.
-
Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg. 2004 Mar; 39(3):448-52; discussion 448-52.